Phase 1 Multiple Sclerosis Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been diagnosed with Primary Progressive Multiple Sclerosis (PPMS) or Relapsing Multiple Sclerosis (RMS), confirmed using a specific set of diagnostic guidelines called the McDonald 2017 criteria
• People whose level of physical disability, as measured by a standard MS scoring tool called the EDSS, falls between 0 and 6.5 at the time of initial assessment

Who may not be able to join:

• People who received a type of medication known as an anti-CD20 therapy (including ocrelizumab) less than 2 years before the initial screening assessment
• People who have an active or suspected infection at the time of screening or at the start of the trial (minor nailbed infections are excepted), or who have had a serious infection requiring hospital care or intravenous antibiotics within the past 8 weeks, or oral antibiotics within the past 2 weeks
• People with a confirmed or suspected history of a serious brain infection called progressive multifocal leukoencephalopathy (PML) (confirm with trial site)
• People who have had any form of cancer, including blood cancers or solid tumours, within the 10 years before screening
• People whose immune system is significantly weakened for any reason
• People who have another condition that would require long-term use of steroid tablets or immune-suppressing medicines during the trial
• People with serious, uncontrolled conditions affecting the heart, lungs, kidneys, liver, hormonal system, or digestive system, or any other significant health condition that may prevent safe participation
• People for whom a standard intravenous (IV) line cannot be placed in an arm or hand vein
• People who have previously been treated with the medications cladribine, atacicept, or alemtuzumab
• People who have taken the medications fingolimod, siponimod, ponesimod, or ozanimod within 6 weeks before the trial start date
• People who have previously had a bone marrow transplant or stem cell transplant of any kind
• People with any history of organ or tissue transplantation, or who have taken anti-rejection medication
• People whose screening blood tests show active, dormant, or inadequately treated hepatitis B infection
• People who are known to be sensitive or intolerant to ocrelizumab or any of its ingredients

Important: Always verify eligibility with the trial site directly before applying.